
NOTHING IS SIMPLE IN ONCOLOGY. **NOTHING BUT BUT THIS.**





THINK IDYLLA[™] BECAUSE TIME MATTERS

MOLECULAR BIOMARKER TESTING WITHIN 3 HOURS FOR FAST TREATMENT INITIATION THINK IDYLLA™



IDYLLA[™] PROVIDES ACCURATE, ACTIONABLE RESULTS WITH DIRECT IMPACT ON TREATMENT CHOICE¹

- Idylla[™] solid biopsy assays focus on clinically relevant mutations
- Clear reporting
- According to clinical guidelines of ASCO, ESMO, NCCN and IASLC²

THERAPEUTIC AREA	GENES	CLINICALLY RELEVANT MUTATIONS	
(FB)	BRAF	7 mutations in codon 600	
	KRAS	21 mutations in codons 12, 13, 59, 61, 117, 146	
	NRAS	18 mutations in codons 12, 13, 59, 61, 117, 146	
	BRAF	5 mutations in codon 600	
	EGFR	51 mutations in exons 18, 19, 20, 21	
	ALK	17 fusions in <i>EML4-, KIF5B-, HIP1-,</i> <i>KLC1-, TPR- & TFG-ALK</i> genes	
	ROS1	13 fusions in CD74-, SDC4-, SLC34A2-, EZR-, TPM3-, GOPC- & LRIG3-ROS1 genes	
	RET	7 fusions in <i>KIF5B- & CCDC6-RET</i> genes	
	METex14	transcript detection at exon 13-exon 15 junction	

MOLECULAR BIOMARKER TESTING WITHIN 3 HOURS FOR FAST TREATMENT INITIATION THINK IDYLLA™





WHY WAIT WEEKS FOR YOUR BIOMARKER RESULTS? THINK IDYLLA™ BECAUSE TIME MATTERS

MOLECULAR TESTING: THE TRADITIONAL VERSUS IDYLLA™ WAY

TRADITIONAL WAY	IDYLLA™ WAY			
\downarrow		\downarrow		
 Centralized & de-centralized testing need for molecular infrastructure highly-skilled molecular technicians 	WHERE	Centralized (in-house) suitable for any hospital lab setting any lab technicians 		
Up to 2 weeks turnaround time of test complex workflow/many manual steps	(?)	<3 hours turnaround time of test ³ fully automated/easy to use		
batching of patient samples 1/week or bi-weekly	нош	single patient samples testing on demand (24/7)		
\downarrow FROM SAMPLE TO TREATMENT INITIATION ¹ \downarrow				
on avg 18 days ^{4,5}		in 1-2 day(s) ^{4,6}		



References

(1) Idylla™ CE IVD Tests are capable of providing same day results intended to aid in the assessment of patients with cancer for their mutation status and to facilitate treatment decisions within a multidisciplinary team.

(2) Most recent guidelines can be found at:

- https://www.esmo.org/Guidelines
- https://www.asco.org/practice-guidelines/quality-guidelines/guidelines
- https://www.nccn.org/professionals/physician_gls/default.aspx
- https://www.iaslc.org/Research-Education/Publications/CAP-IASLC-AMP-Molecular-Testing-Guideline
- (3) Idylla™ Tests Instructions for Use: secure.biocartis.com
- (4) Average waiting time including tissue pre-treatment & pathology review
- (5) Accès aux tests moléculaires EGFR, RAS et BRAF /Résultats d'une enquête dans 5 régions françaises,

appui à la décision, INCa, janvier 2016

(6) Ghigna M et al. Thorac Dis. 2018 Jul; 10(7): 4653-4658

Biocartis NV Generaal de Wittelaan 11B 2800 Mechelen - Belgium +32 15 632 888 www.biocartis.com customerservice@biocartis.com





THINK IDYLLA™ BECAUSE TIME MATTERS

Idylla[™] platform and Idylla[™] BRAF, KRAS, EGFR & NRAS-BRAF Mutation Tests, Idylla[™] MSI Test and Idylla[™] GeneFusion Panel are available as an IVD in Europe and many other countries outside the US. Please check availability with a Biocartis representative. Biocartis and Idylla[™] are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla[™] trademarks and logos are used trademarks owned by Biocartis. © March 2023, Biocartis NV. All rights reserved.